Other limitations to boost anticancer immunity in cancer patients via AnxA1 administration include the high prevalence of a loss-of-function FPR1 allele common in all ethnic groups, which is associated with poor prognosis, at least in breast cancer patients, after anthracycline-based chemotherapy [90,92]. Here, ANXA1 is linked to breast carcinoma.